Tech Company Financing Transactions

Tune Therapeutics Funding Round

Tune Therapeutics, based in Seattle, secured $175 million in investment from New Enterprise Associates, Regeneron Pharmaceuticals and Yosemite.

Transaction Overview

Company Information

Company Status

Private & Independent

Industry

Biopharmaceutical

Mailing Address

1616 Eastlake Ave. East
Seattle, WA 98102
USA

Phone

Undisclosed

Website

www.tunetx.com

Email Address

[email protected]

Overview

Tune Therapeutics, Inc. is orchestrating the power of the epigenome to treat complex, pervasive diseases that have long eluded treatment. With its versatile and powerful TEMPO epigenomic control platform, Tune's experienced team is pioneering a new therapeutic modality that can fine-tune any gene network.

Profile

Social Media

Company News

Facebook

YouTube

Management Team

Title

Name

Email & Social

Chief Executive Officer

Matthew Kane

        

Chief Scientific Officer

Charles Gersbach

        

Co-Founder

Fyodor Urnov

        

Executive Vice President

Heidi Zhang

        

President

Akira Matsuno

        

VP - R & D

Blythe Sather

        

Browse more venture capital transactions:

Prev: 1/13/2025: Kerna Laboratories venture capital transaction
Next: 1/13/2025: Labviva venture capital transaction

Share this article

About Our Venture Capital Transactions Database

We do our best to report on every notable VC transaction. VC investment data records on this site are sourced from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary